Latest News
Web Date: March 19, 2008

Heparin Contaminant Is Chondroitin Sulfate

FDA identifies adulterant in drug lots associated with adverse reactions
Department: Science & Technology
[+]Enlarge
CONTAMINANT
The natural product chondroitin sulfate, already variably sulfated, was chemically modified to introduce additional sulfate groups.
8612NotwCarbs
 
CONTAMINANT
The natural product chondroitin sulfate, already variably sulfated, was chemically modified to introduce additional sulfate groups.

FDA announced on March 19 that in collaboration with academic labs it has identified a contaminant in heparin linked to severe allergic reactions to the drug. The contaminant is chondroitin sulfate (CS), which like heparin is a variably sulfated glycosaminoglycan. CS is found in cartilage and commonly used in the U.S. as a dietary supplement to treat arthritis.

In particular, the CS found in heparin was chemically modified with additional sulfate groups. Such oversulfated, or hypersulfated, CS is not known to exist biologically, and thus it would not have been incorporated into heparin products as an artifact of purification, said Janet Woodcock, director of FDA's Center for Drug Evaluation & Research. Unlike typical CS, oversulfated CS mimics heparin in standard regulatory tests, including potency assays. There is little clinical information on the biological properties of oversulfated heparin, Woodcock added.

FDA is continuing to investigate whether the oversulfated CS was added to heparin accidentally or intentionally, Woodcock said. She noted that CS is abundantly available and inexpensive. CS is commonly isolated from cow and pig cartilage.

The oversulfated CS was found in heparin active pharmaceutical ingredient (API) lots from Scientific Protein Laboratories' (SPL) Changzhou plant in China, as well as the crude heparin used to make the API. In some samples as much as 50% of the API was oversulfated CS. SPL supplied Baxter Healthcare with heparin API. Baxter has recalled its heparin products, as have three Japanese companies—Terumo, Otsuka Pharmaceutical, and Fuso Pharmaceutical Industries—that used heparin API supplied by SPL. German company Rotexmedica GmbH, a unit of the French company Groupe Panpharma, has also recalled heparin sourced from China, although from different suppliers.

FDA and the U.S. Pharmacopeia, which describes itself as the "public standards-setting authority for all prescription and over-the-counter medicines, dietary supplements, and other healthcare products manufactured and sold in the United States," have agreed to expedite development of tests to detect oversulfated CS in heparin. The tests will most likely use nuclear magnetic resonance spectroscopy and capillary electrophoresis, Woodcock said.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment